Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice-Reference-Cited by-同舟云学术

Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

Published:2024-01 Issue:1 Volume:20 Page:24-31
ISSN:1699-258X
Container-title:Reumatología Clínica
language:en
Short-container-title:Reumatología Clínica

Author:

Gratacós-Masmitja Jordi,Beltrán Catalán Emma,Álvarez Vega José Luis,Urruticoechea-Arana Ana,Fito Concepción,Maceiras Francisco,Belzunegui Otano Joaquín María,Fernández Melón Julia,Chamizo Carmona Eugenio,Abad Hernández Miguel Ángel,Ros Vilamajó Inmaculada,Castro Oreiro Sonia,Pascual Alfonso Eva,Torre Alonso Juan Carlos

Funder

Celgene

AbbVie

Publisher

Elsevier BV

Subject

Rheumatology

Reference32 articles.

1. Psoriatic arthritis for the dermatologist;Tintle;Dermatol Clin,2015

2. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis;Coates;Arthritis Rheumatol,2016

3. Economic impact of biologic utilization patterns in patients with psoriatic arthritis;Schwartzman;Clin Rheumatol,2017

4. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update;Gossec;Ann Rheum Dis,2016

5. European Medicines Agency. Otezla – summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003746/WC500182627.pdf.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokines in psoriatic arthritis;Cytokine & Growth Factor Reviews;2024-08